Engineered Mitochondrial Vaccine (IMP3-Mito)
2026(876)
Phase 2 mab active
Quick answer
Engineered Mitochondrial Vaccine (IMP3-Mito) for Head and Neck Squamous Cell Carcinoma is a Phase 2 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Head and Neck Squamous Cell Carcinoma
- Phase
- Phase 2
- Modality
- mab
- Status
- active